Trademark Search in Canada

Hummingbird Bioscience

View On IC.GC.CA

ADVERTISED

on 10 Feb 2025

Last Applicant/ Owned by

Hummingbird Bioscience Pte. Ltd.

#04-01/11, The Aries,Singapore Science Park IISingapore 117586

Serial Number

2143286 filed on 7^th Aug 2021

Registration Number

TMA1289351 registered on 10^th Feb 2025

Registration expiry Date

7^th Aug 2031

Correspondent Address

ROBERT A. FASHLER

c/o VanTek IP LLP101 - 1001 West Broadway, Suite 380VANCOUVER

BRITISH COLUMBIA

V6H4E4

Hummingbird Bioscience

Trademark usage description

monoclonal antibodies for the prevention, diagnosis, and treatment of cancer and auto-immune diseases; monoclonal antibodies for use in the conduct of Read More

Vienna Information

3 . 7 . 16

Birds in flight or with outspread wingsOiseaux en vol ou à ailes largement déployées

3 . 7 . 22

HummingbirdsColibris, oiseaux-mouches

3 . 7 . 24

Birds or bats stylized, in shadow or in silhouetteOiseaux ou chauves-souris stylisés, en ombre ou en silhouette

29 . 1 . 1

Red, pink, orangeRouge, rose, orangé

29 . 1 . 5

VioletViolet

29 . 1 . 4

BlueBleu

29 . 1 . 8

BlackNoir

Classification Information

Class [005]
Monoclonal antibodies for the prevention, diagnosis, and treatment of cancer and auto-immune diseases; Monoclonal antibodies for use in the conduct of scientific research and development, clinical operations, the delivery of medical services, therapeutic services, and diagnostic services, all in the field of cancer and auto-immune diseases; Monoclonal antibodies for use in the treatment cancer and auto-immune diseases; Monoclonal antibodies for treating cancer and auto-immune diseases; Monoclonal antibodies for the treatment of cancer and auto-immune diseases; Monoclonal antibodies for the treatment of cancer; immunological antibodies for medical use, namely, monoclonal antibodies for treating cancer and auto-immune diseases; monoclonal antibodies for treating cancer and auto-immune diseases; monoclonal antibodies for therapeutic purposes, namely, for treating cancer and auto-immune diseases; preparations containing antibodies for use in medicine, namely, monoclonal antibodies for treating cancer and auto-immune diseases; reagents for use in the development of monoclonal antibodies for treating cancer and auto-immune diseases.

Classification kind code

Class [042]
Scientific and technological services and research and design in the field of the development of monoclonal antibodies for treating cancer and auto-immune diseases; industrial analysis and research services in the field of the development of monoclonal antibodies for treating cancer and auto-immune diseases.

Classification kind code

Mark Details

Serial Number

2143286

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 22 on 1^st Feb 2023	Search Recorded
Submitted for opposition 20 on 1^st Feb 2023	Examiner's First Report
Submitted for opposition 223 on 1^st Feb 2023	Total Provisional Refusal
Submitted for opposition 256 on 29^th Aug 2022	Notification of Possible Opposition Sent
Submitted for opposition 80 on 23^rd Jun 2022	Change of Title Registered
Submitted for opposition 257 on 28^th Oct 2021	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 27^th Oct 2021	Formalized
Submitted for opposition 1 on 27^th Oct 2021	Created
Submitted for opposition 228 on 7^th Aug 2021	International Registration
Submitted for opposition 30 on 7^th Aug 2021	Filed